9782 related articles for article (PubMed ID: 17867596)
21. New treatment approaches for prostate cancer based on peptide analogues.
Stangelberger A; Schally AV; Djavan B
Eur Urol; 2008 May; 53(5):890-900. PubMed ID: 18201818
[TBL] [Abstract][Full Text] [Related]
22. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Seitz S; Buchholz S; Schally AV; Weber F; Klinkhammer-Schalke M; Inwald EC; Perez R; Rick FG; Szalontay L; Hohla F; Segerer S; Kwok CW; Ortmann O; Engel JB
BMC Cancer; 2014 Nov; 14():847. PubMed ID: 25410881
[TBL] [Abstract][Full Text] [Related]
23. Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor.
Krebs LJ; Wang X; Pudavar HE; Bergey EJ; Schally AV; Nagy A; Prasad PN; Liebow C
Cancer Res; 2000 Aug; 60(15):4194-9. PubMed ID: 10945629
[TBL] [Abstract][Full Text] [Related]
24. Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH).
Engel JB; Schally AV; Buchholz S; Seitz S; Emons G; Ortmann O
Arch Gynecol Obstet; 2012 Aug; 286(2):437-42. PubMed ID: 22555802
[TBL] [Abstract][Full Text] [Related]
25. Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207.
Arencibia JM; Bajo AM; Schally AV; Krupa M; Chatzistamou I; Nagy A
Anticancer Drugs; 2002 Oct; 13(9):949-56. PubMed ID: 12394258
[TBL] [Abstract][Full Text] [Related]
26. LH-RH receptors in human colorectal cancers: unexpected molecular targets for experimental therapy.
Szepeshazi K; Schally AV; Halmos G
Int J Oncol; 2007 Jun; 30(6):1485-92. PubMed ID: 17487370
[TBL] [Abstract][Full Text] [Related]
27. Antitumor effects of the cytotoxic luteinizing hormone-releasing hormone analog AN-152 on human endometrial and ovarian cancers xenografted into nude mice.
Gründker C; Völker P; Griesinger F; Ramaswamy A; Nagy A; Schally AV; Emons G
Am J Obstet Gynecol; 2002 Sep; 187(3):528-37. PubMed ID: 12237622
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma.
Hashmi MH; Van Veldhuizen PJ
Expert Opin Biol Ther; 2010 May; 10(5):807-17. PubMed ID: 20384523
[TBL] [Abstract][Full Text] [Related]
29. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone.
Engel JB; Schally AV
Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):157-67. PubMed ID: 17237842
[TBL] [Abstract][Full Text] [Related]
30. Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones.
Engel JB; Schally AV; Dietl J; Rieger L; Hönig A
Mol Pharm; 2007; 4(5):652-8. PubMed ID: 17705441
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy targeted to cancers through tumoral hormone receptors.
Schally AV; Nagy A
Trends Endocrinol Metab; 2004 Sep; 15(7):300-10. PubMed ID: 15350601
[TBL] [Abstract][Full Text] [Related]
32. Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins.
Keller G; Schally AV; Nagy A; Baker B; Halmos G; Engel JB
Int J Oncol; 2006 Jun; 28(6):1507-13. PubMed ID: 16685451
[TBL] [Abstract][Full Text] [Related]
33. Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors.
Emons G; Kaufmann M; Gorchev G; Tsekova V; Gründker C; Günthert AR; Hanker LC; Velikova M; Sindermann H; Engel J; Schally AV
Gynecol Oncol; 2010 Dec; 119(3):457-61. PubMed ID: 20828803
[TBL] [Abstract][Full Text] [Related]
34. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice.
Miyazaki M; Schally AV; Nagy A; Lamharzi N; Halmos G; Szepeshazi K; Armatis P
Am J Obstet Gynecol; 1999 May; 180(5):1095-103. PubMed ID: 10329861
[TBL] [Abstract][Full Text] [Related]
35. Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer.
Liu SV; Liu S; Pinski J
Expert Opin Investig Drugs; 2011 Jun; 20(6):769-78. PubMed ID: 21449823
[TBL] [Abstract][Full Text] [Related]
36. In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses.
Arencibia JM; Schally AV; Halmos G; Nagy A; Kiaris H
Anticancer Drugs; 2001 Jan; 12(1):71-8. PubMed ID: 11272290
[TBL] [Abstract][Full Text] [Related]
37. New approaches to the therapy of various tumors based on peptide analogues.
Schally AV
Horm Metab Res; 2008 May; 40(5):315-22. PubMed ID: 18491250
[TBL] [Abstract][Full Text] [Related]
38. Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness.
Arencibia JM; Schally AV; Krupa M; Bajo AM; Nagy A; Szepeshazi K; Plonowski A
Int J Oncol; 2001 Sep; 19(3):571-7. PubMed ID: 11494038
[TBL] [Abstract][Full Text] [Related]
39. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency.
Schottelius M; Berger S; Poethko T; Schwaiger M; Wester HJ
Bioconjug Chem; 2008 Jun; 19(6):1256-68. PubMed ID: 18510351
[TBL] [Abstract][Full Text] [Related]
40. Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer.
Engel JB; Tinneberg HR; Rick FG; Berkes E; Schally AV
Curr Drug Targets; 2016; 17(5):488-94. PubMed ID: 26951061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]